Cystic fibrosis, one of the most common genetic diseases in Switzerland, promotes chronic bacterial infections by impairing ...

TIMBERLINE study shows good safety and sweat chloride reductions with triple combo CFTR mo ...

Ride Therapeutics (´Ride´or ´the Company´), an engineering and machine learning powered biotechnology company committed to solving the delivery challenge for genetic medicines, today announced a ...

Vertex Pharmaceuticals (NASDAQ:VRTX) highlighted a series of upcoming clinical, regulatory and commercial catalysts across ...

Breathing disorders are common in the U.S. with conditions like COPD affecting some 7% of the population and asthma affecting another 10%. Digestive conditions like GERD, acid reflux, Celiac disease ...

People with cystic fibrosis do not usually have a higher risk of COVID-19 when compared to people without this condition. They also typically have an infection course similar to people without cystic ...

Supportive therapy, like medications to help open the airways and heal infections, can help you live a healthier life and meet many of the challenges of this inherited respiratory condition. Share on ...

A UNIGE team has succeeded in restoring the defective respiratory protective barrier in people with this rare genetic disease ...

For decades, lung disease has been the most visible and life-threatening part of cystic fibrosis. People might picture chronic (long-term) cough, breathlessness, recurrent chest infections and oxygen ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) could be positioning itself for its next major phase of growth following its roughly $10 billion acquisition of Crinetics Pharmaceuticals. The deal ...

Alyftrek (vanzacaftor/tezacaftor/deutivacaftor) is a combination medicine approved by the FDA in 2024. Alyftrek is approved to treat people ages 6 and older who have ...

Northwest Arkansas Food Bank backers gathered for the second annual Flavor of Giving fundraiser Aug. 27 at Osage House in ...